Pentobarbital is a drug within the barbiturate class that works primarily on the central nervous system. At low doses, indications include short-term sedative for the treatment of insomnia, and as a pre-anesthetic for surgery. At higher doses, pentobarbital serves as an anticonvulsant for emergent seizure control and medically induced comas. Pentobarbital is often subject to comparison with phenobarbital, another barbiturate, in the use of refractory status epilepticus. Studies have found that pentobarbital is superior in that it has faster brain penetration and a shorter half-life, making it the treatment of choice.
Common off-label uses are for control of intracranial pressure in patients with severe brain injuries, cerebral ischemia, and those receiving treatment for Reye syndrome. Some US states use it for capital punishment, but this remains a widely controversial topic, and some manufacturers do not allow its sale to prisons. More commonly, it is used by veterinarians for euthanasia and anesthesia.
Pentobarbital works in the central nervous system by binding to gamma-aminobutyric acid (GABA) A subtype receptors. This action induces a change in the chloride transport receptor leading to an increase in the duration that the chloride channels remain open, and hence potentiating the effects of GABA. GABA is responsible for producing CNS depression and thus prolonging the time the channels remain open intensifies the depressant effects on the CNS. Pentobarbital also works by inhibiting glutamate, which is responsible for nerve depolarization in the voltage-activated calcium currents. This activity is an additive effect on CNS depression. It undergoes first-pass metabolism in the liver.
Pentobarbital administration can be through three routes: intramuscular, intravenous, or oral. For intramuscular administration, it is advised to inject no more than 5 ml and only into a large muscle to avoid tissue irritation or necrosis. Intravenous administration is not to exceed 50 mg/minute and should only be given by slow IV injection in the undiluted form. It is essential to avoid tissue extravasation in this process as it has been known to cause tissue necrosis. Clinicians should avoid rapid IV injection as it can result in respiratory depression, hypotension, and bronchospasm, among other adverse effects. In pediatric populations, oral administration is easier by mixing the drug with flavored syrup to improve the taste.
The main adverse reactions surrounding pentobarbital use are central nervous system effects, which include altered mental status, agitation, confusion, drowsiness, respiratory depression, bradycardia, hypotension, cardiovascular collapse, and syncope. Other significant side effects to be aware of include hallucinations, headache, insomnia, nausea, vomiting, hepatoxicity, megaloblastic anemia, angioedema, local injection site reactions, laryngospasm, bronchospasm, apnea, and hyperkinesia.
Contraindications to pentobarbital use include any prior hypersensitivity reactions to previous drug use or barbiturate class use. Other contraindications include patients with depressed respiratory function and porphyria. Avoid abrupt drug withdrawal in those on long-term therapy. It is advised to use with caution in the elderly, those with renal impairment, hepatic impairment, and those with drug use history.
Barbiturates have been shown to cause fetal damage if used in pregnant women and are pregnancy category D drugs. This class of drugs can cross the placental barrier and distribute throughout the fetal tissue with the highest concentrations found in the liver, brain, and placenta. It is essential to monitor maternal blood levels for fetal safety in any pregnant lady taking these drugs. There is documentation of withdrawal in infants born to mothers who took barbiturates during pregnancy. Newborns should be closely monitored for seizures and hyperirritability as this may indicate a need for withdrawal treatment. Symptoms can be delayed for up to two weeks and require prompt treatment if indicated.
Toxic doses of pentobarbital occur at approximately 1 gram in most adults with death occurring at 2 to 10 grams. The therapeutic values for pentobarbital depend on the intended therapeutic effect. For sedation, it is 1 to 5 mcg/mL. For intracranial pressure therapy, it is 30 to 40 mcg/mL, and for therapeutic coma, it is 20 to 50 mcg/mL. Toxic values for sedation are greater than 10 mcg/mL. Time to steady-state in adults is 3 to 6 days. Monitoring parameters include EEG and serum drug levels. Other things to consider when assessing for toxicity are a complete blood count (CBC), liver function tests (LFTs), and a blood urea nitrogen (BUN) to creatinine ratio if on continuous treatment. Clinicians need to be aware that pentobarbital is often confused with phenobarbital, a different drug with varying dosage differences.
Pentobarbital is a high-risk habit-forming drug that is under control by the Federal Controlled Substances Act under DEA schedule II. Tolerance, physical dependence, and psychological effects can occur in patients with long term use. Estimates are that beyond 400 mg daily for greater than 90 days is the threshold for developing a dependence. Doses of 600 to 800 mg daily for greater than 35 days correlate withdrawal seizures. Symptoms of acute intoxication include gait and speech alterations, and neurological manifestations. Chronic intoxication demonstrates confusion, agitation, insomnia, and generalized myalgias. Minor withdrawal is seen within 8 to 12 hours and major withdrawal within 16 hours, lasting for up to one week following cessation of the drug. Treatment of dependence includes close monitoring and gradual withdrawal of the drug by small dosage decreases over many weeks. Infants with physical dependence commonly present with hyperactivity, sleep disturbances, and hyperreflexia. Treatment of withdrawal in this population usually spans over two weeks.
Treatment of pentobarbital toxicity involves supportive care, as there is no antidote. Overdose can lead to airway compromise, cardiovascular collapse, coma, and death. Treatment often requires intubation, hemodynamic support with vasopressors, and maintaining body temperature with warmers commonly in an ICU setting. In mild or early cases of toxicity, activated charcoal and alkaline diuresis have been added but show minimal benefits. Always contact poison control if poisoning or overdose is suspected.
Special care is necessary for those with renal and hepatic impairment. For renal impairment, the manufacturer does not provide dosage adjustment recommendations, but it is essential to monitor kidney function if using high doses or before undergoing prolonged treatment. Similar effects occur in those with hepatic impairment, and recommendations are for close patient monitoring.
Pentobarbital interacts with several major classes of drugs and requires close monitoring to ensure therapeutic drug levels are maintained. As a class, barbiturates induce hepatic microsomal enzymes which increase the rate of metabolism of other drugs metabolized by these hepatic enzymes. In particular, anticoagulants can be affected, and patients taking these drugs, predominantly Warfarin, may require dosage adjustments. Other drug interactions to be aware of include levothyroxine, corticosteroids, doxycycline, phenytoin, valproic acid, alcohol, monoamine oxidase inhibitors (MAOI's), and some hormones such as estradiol, estrone, and progesterone to name a few.
Pentobarbital is not used widely in clinical medicine because of its poor safety, habituation, and lack of an antidote. All clinicians who prescribe should be aware of its toxicity and side effect profile.
Withdrawal from pentobarbital can be life-threatening. Managing pentobarbital withdrawal requires a well trained interprofessional team of healthcare professionals that includes nurses, pharmacists, and several physicians from different specialties. Without proper management, the morbidity and mortality from unrecognized pentobarbital withdrawal are high. Properly treating pentobarbital withdrawal begins the moment a health care provider recognizes the patient is either susceptible to or suffering from withdrawal. The moment that withdrawal is suspected, the interprofessional team must coordinate the care for the patient, including:
To avoid the high potential for morbidity and mortality associated with pentobarbital, the pharmacist should recommend prescribing clinicians safer alternative agents. Nursing should monitor the patient at subsequent visits, verifying medication compliance and treatment effectiveness. With an interprofessional team approach, the morbidity of pentobarbital is reducible, and clinical success optimized. [Level 5].
|||Abou Khaled KJ,Hirsch LJ, Updates in the management of seizures and status epilepticus in critically ill patients. Neurologic clinics. 2008 May; [PubMed PMID: 18514819]|
|||Adelson PD,Bratton SL,Carney NA,Chesnut RM,du Coudray HE,Goldstein B,Kochanek PM,Miller HC,Partington MD,Selden NR,Warden CR,Wright DW, Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 13. The use of barbiturates in the control of intracranial hypertension in severe pediatric traumatic brain injury. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2003 Jul; [PubMed PMID: 12847349]|
|||Holtkamp M,Masuhr F,Harms L,Einhäupl KM,Meierkord H,Buchheim K, The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists. Journal of neurology, neurosurgery, and psychiatry. 2003 Aug; [PubMed PMID: 12876241]|
|||Walker SE,Iazzetta J, Compatibility and stability of pentobarbital ininfusions. Anesthesiology. 1981 Oct; [PubMed PMID: 7294399]|
|||Wermeling DP,Blouin RA,Porter WH,Rapp RP,Tibbs PA, Pentobarbital pharmacokinetics in patients with severe head injury. Drug intelligence [PubMed PMID: 3582175]|
|||Knodell RG,Spector MH,Brooks DA,Keller FX,Kyner WT, Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat. Gastroenterology. 1980 Dec; [PubMed PMID: 6777235]|
|||Ehrnebo M, Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration. Journal of pharmaceutical sciences. 1974 Jul; [PubMed PMID: 4853598]|
|||American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr; [PubMed PMID: 30693946]|
|||Ashtarinezhad A,Panahyab A,Shaterzadeh-Oskouei S,Khoshniat H,Mohamadzadehasl B,Shirazi FH, Teratogenic study of phenobarbital and levamisole on mouse fetus liver tissue using biospectroscopy. Journal of pharmaceutical and biomedical analysis. 2016 Sep 5; [PubMed PMID: 27262993]|
|||Preuss CV,Kalava A,King KC, Prescription of Controlled Substances: Benefits and Risks 2019 Jan; [PubMed PMID: 30726003]|
|||Singh V, Survival after fatal pentobarbital ingestion. Indian journal of anaesthesia. 2014 Jan; [PubMed PMID: 24700912]|